<SEC-DOCUMENT>0001104659-21-061726.txt : 20210505
<SEC-HEADER>0001104659-21-061726.hdr.sgml : 20210505
<ACCEPTANCE-DATETIME>20210505161540
ACCESSION NUMBER:		0001104659-21-061726
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210505
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210505
DATE AS OF CHANGE:		20210505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		21893454

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2111672d3_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event reported):&nbsp;May
5, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 34%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-12584</B></FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>13-3808303</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation)</P></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File No.)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer Identification</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">No.)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9605 Medical Center Drive, Suite 270</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rockville, Maryland 20850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(301) 417-4364</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border: black 1pt solid; padding-left: 6.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 34%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Common stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">SYN</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">NYSE American</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by checkmark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.02 &#8211; Results of Operations and
Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 5, 2021, Synthetic
Biologics, Inc., a Nevada corporation (the &#8220;Registrant&#8221;) issued a press release that included financial information for its
quarter ended March 31,2021. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information
contained in the press release is being furnished to the Securities and Exchange Commission (the &#8220;Commission&#8221;) and shall not
be deemed incorporated by reference into any of the Registrant&#8217;s registration statements or other filings with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01 &#8211; Financial Statements and Exhibits.&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">(d)&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 99%; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">Exhibits.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
    Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 89%; border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="tm2111672d3_ex99-1.htm">99.1</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="tm2111672d3_ex99-1.htm">Press
    Release issued by Synthetic Biologics, Inc., dated May 5, 2021</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">Dated: May 5, 2021</FONT></TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt"><FONT STYLE="font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 41%; padding-right: 0.8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt"><FONT STYLE="font-size: 10pt">/s/ Steven A. Shallcross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">Steven A. Shallcross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">and Chief Financial Officer</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2111672d3_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font-family: Arial, Helvetica, Sans-Serif">


<P STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2111672d3_ex99-1img01.jpg" ALT="" STYLE="width: 214pt"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Reports 2021 First Quarter
Operational Highlights and Financial Results</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B><I>Initiated Phase 1b/2a Clinical Trial of SYN-004
in Allogeneic HCT Recipients for the Prevention of aGVHD</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B><I>Initiated Phase 1a Single-Ascending-Dose
Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B><I>Reports $76.9 Million of Cash on Hand to
Fund Clinical Programs Through Proof-of-Concept </I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B><I>and Extend Operations into 2023</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B><I>-- Conference Call Today at 4:30 p.m. (ET)
--</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Rockville,
MD, May 5, 2021 &ndash;</B></FONT> Synthetic Biologics, Inc. <FONT STYLE="color: windowtext">(NYSE American: SYN),</FONT> a diversified
clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases
in areas of high unmet need, <FONT STYLE="color: windowtext">today provided a clinical programs update and reported financial results
for the quarter ended March 31, 2021.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.7in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Recent developments:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Announced enrollment has commenced and three out of a total of four cohorts have been dosed in the first
Phase 1a clinical trial of SYN-020 intestinal alkaline phosphatase (&ldquo;IAP&rdquo;) intended to support development of SYN-020 in multiple
indications</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Announced enrollment has commenced and the first patient was dosed in the Phase 1b/2a clinical trial of
SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (&ldquo;HCT&rdquo;) recipients</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Current cash position of approximately $76.9 million</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Received $8.0 million from the exercise of warrants</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">Current cash runway provides funding into 2023 and ability to fund Phase
1b/2a clinical trial of SYN-004 as well as SYN-020 </FONT>intestinal alkaline phosphatase (&ldquo;IAP&rdquo;) through proof-of-concept</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Upcoming milestones, pandemic conditions permitting:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Topline data from the Phase 1a single-ascending-dose (&ldquo;SAD&rdquo;) study of SYN-020 anticipated
during Q3 2021</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Expect to commence second Phase 1a multiple-ascending-dose (&ldquo;MAD&rdquo;) study of SYN-020 during
Q3 2021; topline data anticipated during Q2 2022</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Topline data readout from the first antibiotic cohort of the SYN-004 Phase1b/2a clinical trial is expected
during Q4 2021</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.7in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&ldquo;During the first quarter of 2021 we remained
diligently focused on advancing our portfolio of GI and microbiome-focused clinical programs and were pleased to announce the commencement
of clinical trials for our SYN-004 and SYN-020 programs,&rdquo; said Steven A. Shallcross, Chief Executive Officer of Synthetic Biologics.
 &ldquo;Enrollment in the SYN-004 Phase 1b/2a clinical trial in allogeneic hematopoietic cell transplant (HCT) recipients is underway at
the Washington University School of Medicine in St. Louis (&ldquo;Washington University&rdquo;) and the first patient of the first antibiotic
cohort was dosed earlier this year. We believe SYN-004 has the potential to address an important and underserved patient population, and
may significantly improve outcomes for allogeneic HCT recipients by preventing downstream complications often associated with disruption
of the gut microbiome by intravenous (&ldquo;IV&rdquo;) beta-lactam antibiotics. If enrollment proceeds as planned, we anticipate announcing
topline data from the first antibiotic cohort during the fourth quarter of 2021, pandemic conditions permitting.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Mr. Shallcross continued, &ldquo;We were also
very excited to announce the initiation of a Phase 1a single-ascending-dose clinical trial of our SYN-020 IAP program during the first
quarter of 2021. To date, three out of a total of four cohorts have been dosed and we remain on track to report topline data from this
study during the third quarter of 2021, pandemic conditions permitting. A second Phase 1a multiple-ascending-dose study is also expected
to begin enrollment during the third quarter of 2021 with topline data expected early next year. Both studies are designed to support
the advancement of SYN-020 in multiple potential therapeutic indications, including celiac disease, nonalcoholic fatty liver disease (&ldquo;NAFLD&rdquo;)
and age-related metabolic and inflammatory diseases. We are very excited about the potential for this program to be a long-term value
driver for our Company and look forward to sharing important updates.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Mr. Shallcross concluded, &ldquo;While we remain
focused on the execution of our clinical development activities, we were also able raise net proceeds of approximately $66 million as
well as $8.0 million in proceeds from the cash exercise of warrants, significantly strengthening our balance sheet and financial position.
As a result of these activities, our current cash position is approximately $76.9 million. Importantly, our fortified balance sheet will
fully fund our SYN-004 and SYN-020 clinical programs through proof-of-concept clinical studies, and help accelerate our other ongoing
activities.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><U>Clinical Development and Operational Update</U></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Announced Washington University has begun enrollment and the first patient was dosed in the first antibiotic
cohort of the Company&rsquo;s Phase 1b/2a clinical trial of SYN-004 in allogeneic HCT recipients for the prevention of acute graft-versus-host-disease
(aGVHD)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">o</FONT></TD><TD STYLE="text-align: justify">The Phase 1b/2a clinical trial comprises a single center, randomized, double-blind, placebo-controlled
clinical trial of oral SYN-004 in up to 36 evaluable adult allogeneic HCT recipients,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">o</FONT></TD><TD STYLE="text-align: justify">The goal of this clinical trial is to evaluate the safety, tolerability and potential absorption into
the systemic circulation (if any) of oral SYN-004 administered to allogeneic HCT recipients who receive an IV beta-lactam antibiotic to
treat fever,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">o</FONT></TD><TD STYLE="text-align: justify">Study participants will be enrolled into three sequential cohorts and administered a different study-assigned
IV beta-lactam antibiotic. Eight participants in each cohort will receive SYN-004 and four will receive placebo,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">o</FONT></TD><TD STYLE="text-align: justify">Safety and pharmacokinetic data for each cohort will be reviewed by an independent Data and Safety Monitoring
Committee (&ldquo;DSMC&rdquo;), which will make a recommendation on whether to proceed to the next IV beta-lactam antibiotic,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">o</FONT></TD><TD STYLE="text-align: justify">A topline data readout for the first antibiotic cohort is anticipated during the fourth quarter of 2021,
pandemic conditions permitting;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Announced enrollment has commenced and three out of a total of four cohorts have been dosed in a Phase
1a SAD clinical trial of SYN-020 in healthy adult volunteers</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">The Phase 1a SAD study is designed to evaluate safety, tolerability and
pharmacokinetics of four single-ascending doses of oral SYN-020 in healthy adult volunteers</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">o</FONT></TD><TD STYLE="text-align: justify">In all, up to 24 study participants will be enrolled into four cohorts that will run sequentially, all of which will receive oral SYN-020. A topline data readout is anticipated during the third quarter of 2021, pandemic conditions permitting,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">o</FONT></TD><TD STYLE="text-align: justify">A second Phase 1a clinical trial evaluating multiple-ascending doses of SYN-020 in healthy volunteers
is expected to commence during the third quarter of 2021. Topline data is anticipated during the second quarter of 2022, pandemic conditions
permitting,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">o</FONT></TD><TD STYLE="text-align: justify">Both studies are intended to support the development of SYN-020 in multiple potential clinical indications
including celiac disease, NAFLD, and indications supported by the Company&rsquo;s collaboration with Massachusetts General Hospital;</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Strengthened balance sheet by raising net proceeds of $66 million from the sale of common stock via the
Company&rsquo;s At-The-Market (&ldquo;ATM&rdquo;) facility and $8.0 million resulting from the cash exercise of a portion of Company&rsquo;s
2018 warrants during Q1 2021</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">o</FONT></TD><TD STYLE="text-align: justify">As a result of these activities, the Company has extended its cash runway into 2023 and has the ability
to fully fund its Phase 1b/2a clinical trial of SYN-004 and planned Phase 1 SAD and MAD clinical trials of SYN-020.</TD></TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><U>Quarter Ended March 31, 2020 Financial Results</U></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">General and administrative expenses increased
by 2% to approximately $1.42 million for the three months ended March 31, 2021, from approximately $1.39 million for the three months
ended March 31, 2020. This increase is primarily due to higher insurance costs, audit fees, and legal costs offset by a reduction in patent
related legal fees, consulting fees and travel expense. The charge related to stock-based compensation expense was $82,000 for the three
months ended March 31, 2021, compared to $65,000 the three months ended March 31, 2020.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Research and development expenses decreased by
32% to approximately $1.1 million for the three months ended March 31, 2021, from approximately $1.6 million for the three months ended
March 31, 2020. This decrease is primarily the result of lower indirect program costs for the three months ended March 31, 2021, including
salary and related expense reductions, a decrease in manufacturing costs for SYN-020 and market research. In addition, as a result of
the global COVID-19 pandemic, the Company&rsquo;s development partner (Washington University) reduced their operating capacity during
2021 to include only essential activities as part of their pandemic response, which delayed the start of the Company&rsquo;s clinical
trial, resulting in lower clinical trial expenses for the quarter. The research and development costs incurred during the quarter were
primarily related to the Company&rsquo;s Phase 1a clinical trial of SYN-020 and the Phase 1b/2a clinical trial of SYN-004 (ribaxamase)
in allogeneic HCT recipients. The Company anticipates research and development expense to increase as ongoing clinical trials continue
to enroll patients. The charge related to stock-based compensation expense was $19,000 for the three months ended March 31, 2021, compared
to $18,000 related to stock-based compensation expense for the three months ended March 31, 2020.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Other income was $347 for the three months ended
March 31, 2021, compared to other income of $38,000 for the three months ended March 31, 2020. Other income for the three months ended
March 31, 2021 and 2020 is primarily comprised of interest income.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents as of March 31, 2021
totaled $76.9 million, an increase of $70.7 million from December 31, 2020.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics will hold a conference call today, Wednesday, May
5<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">, 2021, at 4:30 p.m. (EST).</FONT> The dial-in information
for the call is as follows, U.S. toll free: 1-888-347-5280 or International: +1 412-902-4280. Participants are asked to dial in 15 minutes
before the start of the call to register. The call will also be webcast over the Internet at https://www.webcaster4.com/Webcast/Page/1096/40931.
An archive of the call will be available for replay at the same URL, https://www.webcaster4.com/Webcast/Page/1096/40931 , for 90 days
after the call.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE American: SYN)
is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal
(GI) diseases in areas of high unmet need. The Company&rsquo;s lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade
certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage,
(b) <I>Clostridioides difficile</I> infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance
(AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020,
a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat
both local GI and systemic diseases. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified
by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot; &quot;anticipates,&quot;
 &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and similar expressions, and include statements regarding
the first Phase 1a clinical trial of SYN-020 supporting development of SYN-020 in multiple indications; topline data from the Phase 1a
single-ascending-dose (&ldquo;SAD&rdquo;) study of SYN-020 during Q3 2021, commencing a second Phase 1a multiple ascending-dose (&ldquo;MAD&rdquo;)
study of SYN-020 during Q3 2021 and topline data anticipated during Q2 2022, topline data readout from the first antibiotic cohort of
the SYN-004 Phase 1b/2a clinical trial during Q4 2021, SYN-004 having the potential to address an important and underserved patient population,
and significantly improving outcomes for allogeneic HCT recipients by preventing downstream complications often associated with disruption
of the gut microbiome by intravenous (&ldquo;IV&rdquo;) beta-lactam antibiotics. If enrollment proceeds as planned, we anticipate announcing
topline data from the first antibiotic cohort during the fourth quarter of 2021, pandemic conditions permitting, SYN-020 program being
a long-term driver for Synthetic Biologics, the financial footing allowing Synthetic Biologics to continue its operations into 2023 as
well as fully fund its SYN-004 and SYN-020 clinical programs through proof-of-concept clinical studies. These forward-looking statements
are based on management&rsquo;s expectations and assumptions as of the date of this press release and are subject to a number of risks
and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations
and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to
differ materially from current expectations include, among others, a failure to receive the necessary regulatory approvals for commercialization
of Synthetic Biologics&rsquo; therapeutics, a failure of Synthetic Biologics&rsquo; clinical trials for SYN-004 and SYN-020 to be completed
on time, to provide topline data when anticipated or to achieve desired results and benefits, especially in light of COVID-19, a failure
of Synthetic Biologics&rsquo; clinical trials to continue enrollment as expected or receive anticipated funding, a failure of Synthetic
Biologics to successfully develop, market or sell its products, Synthetic Biologics&rsquo; inability to maintain its material licensing
agreements, or a failure by Synthetic Biologics or its strategic partners to successfully commercialize products and other factors described
in Synthetic Biologics&rsquo; Annual Report on Form 10-K for the year ended December 31, 2020 and its other filings with the SEC, including
subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and
Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information,
future events, or otherwise, except as required by law.</I></P>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and Investors)</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Vincent I. Perrone, Director Corporate Communication, (240) 660-2000,
info@syntheticbiologics.com</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Ogilvy (Media)</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Gregory Kelley, Senior Vice President, (404) 836-2302, gregory.kelley@ogilvy.com</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><I>- Financial Tables Follow -</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><I>&nbsp;<BR STYLE="clear: both">
</I></P>

<P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Synthetic Biologics, Inc. and Subsidiaries</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B><I>(in thousands, except share and per share amounts)</I></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Consolidated Balance Sheets</B></FONT> </P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; border-bottom: Black 1pt solid">March 31, 2021</TD><TD STYLE="border-top: Black 1pt solid; padding-bottom: 1pt; font: bold 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;&nbsp;&nbsp;Cash and cash equivalents</TD><TD STYLE="width: 2%; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">76,887</TD><TD STYLE="width: 1%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">6,227</TD><TD STYLE="width: 1%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">1,749</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">1,707</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;&nbsp;&nbsp;Property and equipment, net</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">156</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">174</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;&nbsp;&nbsp;Right of Use Asset</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">239</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">279</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Deposits and other assets</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">79,054</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">8,410</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left">Liabilities and Stockholder&rsquo;s Deficit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;&nbsp;&nbsp;Total liabilities</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">2,230</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">3,152</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;&nbsp;&nbsp;Series A Convertible Preferred Stock</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">-</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">12,798</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-left: 0.1in">Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">79,598</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(4,767</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-left: 0.1in">Non-controlling interest</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(2,774</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(2,773</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&rsquo; Equity (Deficit)</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">79,054</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">8,410</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Condensed Consolidated Statements of Operations</B></FONT> &nbsp; &nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; border-bottom: Black 1pt solid">For the three months ended<BR> March 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left">Operating Costs and Expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;&nbsp;&nbsp;General and administrative</TD><TD STYLE="width: 2%; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">1,419</TD><TD STYLE="width: 1%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">1,393</TD><TD STYLE="width: 1%; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Research and development</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">1,118</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">1,635</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt">Total Operating Costs and Expenses</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">2,537</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">3,028</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt">Loss from Operations</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(2,537</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(3,028</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left">Other Income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Interest income</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">38</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt">Total Other Income</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">38</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>&nbsp;</B></P><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Net Loss </B></P></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(2,537</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(2,990</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt">Net Loss Attributable to Non-controlling Interest</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(1</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(26</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 2.5pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Net Loss Attributable to Synthetic Biologics, Inc. </B></P> <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>and Subsidiaries</B></P></TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(2,536</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(2,964</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: normal 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt; text-indent: 4.6pt">Series A Preferred Stock Dividends</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(24</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(62</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: normal 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt; text-indent: 4.6pt">Effect of Series A Preferred Stock price adjustment</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(7,402</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: normal 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1pt; text-indent: 4.6pt">Series B Preferred Stock Dividends</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(1,497</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(404</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 2.5pt; text-indent: 0.1pt">Net Loss Attributable to Common Stockholders</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(11,459</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(3,430</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share - Basic and Dilutive</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(0.13</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">(0.20</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding - Basic and Dilutive</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">90,807,693</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial, Helvetica, Sans-Serif; text-align: right">17,093,920</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><BR STYLE="clear: both">
</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2111672d3_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2111672d3_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #C F # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6P_-&:9FMGP_I(U*X:2;/V>+&1_>/I6M##SKU%3ANR*LXTX.<MD4+>RNKO\
MU$$D@]57C\Z?/IM[;)OFM954=6VY KT-$2- B*%51@ # %.KZ-</4^76;O\
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MZ;;Z/I5KIUJ@6&WC"* .N.I/N3S^-5*7*M!17-N?+NM^%]:\.,@U;3Y+8/\
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M?4E?(>H_\A.[_P"NS_\ H1KZ\KY%U6-HM8O8W&&2XD4CW#&II=1U#V'X%_\
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MS)U$3C."1Z'.#^%4V[71*6MF9G_"LO&/_0$D_P"_T?\ \51_PK+QC_T!)/\
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M?:-\PBV^9LQD$YS@^E6=#U3^VM'@U#R?)\W=^[W;L88KUP/2N>^)7_(N6_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $90P(8 @]0:S;C
MP]HUR29=,M2QZL(PI/XBM.BIE&,MU<N%2<-8MKT9SK^!O#SG/V J2<_+,_\
MC0G@;P\C9^PEL=FF?'\ZZ*BL_J]+^5?<;?7<3M[1_>RA::)I=B0UM86\;#^(
M1C=^?6K]%%:J*BK)&$IRF[R=PHHHIDA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
